Biogen Inc. (NASDAQ: BIIB) had its "neutral" rating re-affirmed by analysts at BTIG Research.
Biogen Inc. (BIIB)
Last biogen inc. earnings: 4/22 07:12 am
Check Earnings Report
US:NASDAQ Investor Relations:
biogen.com/en_us/investors.html
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
BIIB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIIB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIIB alerts
High impacting Biogen Inc. news events
Weekly update
A roundup of the hottest topics
BIIB
News
- Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio [Yahoo! Finance]Yahoo! Finance
- Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into NephrologyGlobeNewswire
- Biogen high-dose Spinraza approval seen supporting long-term growth [Yahoo! Finance]Yahoo! Finance
- FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy [Yahoo! Finance]Yahoo! Finance
- FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular AtrophyGlobeNewswire
BIIB
Earnings
- 2/9/26 - Beat
BIIB
Sec Filings
- 3/31/26 - Form 8-K
- 3/26/26 - Form SCHEDULE
- 3/11/26 - Form 8-K
- BIIB's page on the SEC website